Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors
- PMID: 23162612
- PMCID: PMC3499618
- DOI: 10.3892/ol.2012.872
Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors
Abstract
Lung-specific toxicity induced by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer (NSCLC) has emerged as a critical side-effect. Although the clinical features of the pulmonary side-effects of TKIs have been characterized, the details of the molecular mechanisms in the development of this lung-specific toxicity remain to be elucidated. EGFR-dependent epithelial regeneration and restoration plays an important role in the recovery process from lung injury. The lung comprises a unique environment where epithelial cells are exposed to internal agents in the systemic circulation and to airborne particles through the mouth and nose. This unique environment may also be associated with the development of lung-specific toxicity induced by EGFR-TKIs. Therefore, the aim of this review was to provide further insight into the molecular mechanisms of lung-specific toxicity in the context of treatment with EGFR-TKIs.
Similar articles
-
Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.Oncotarget. 2015 Dec 29;6(42):44332-45. doi: 10.18632/oncotarget.6293. Oncotarget. 2015. PMID: 26554308 Free PMC article.
-
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12. Cancer Treat Rev. 2013. PMID: 23768755 Review.
-
Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?Curr Opin Oncol. 2017 Mar;29(2):89-96. doi: 10.1097/CCO.0000000000000350. Curr Opin Oncol. 2017. PMID: 28085680 Review.
-
Mechanisms of resistance to EGFR tyrosine kinase inhibitors.Acta Pharm Sin B. 2015 Sep;5(5):390-401. doi: 10.1016/j.apsb.2015.07.001. Epub 2015 Jul 26. Acta Pharm Sin B. 2015. PMID: 26579470 Free PMC article. Review.
-
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23. Lung Cancer. 2019. PMID: 31568888 Free PMC article. Review.
Cited by
-
Deciphering the scalene association among type-2 diabetes mellitus, prostate cancer, and chronic myeloid leukemia via enrichment analysis of disease-gene network.Cancer Med. 2019 May;8(5):2268-2277. doi: 10.1002/cam4.1845. Epub 2019 Apr 1. Cancer Med. 2019. PMID: 30938105 Free PMC article.
-
Anticancer therapy and lung injury: molecular mechanisms.Expert Rev Anticancer Ther. 2018 Oct;18(10):1041-1057. doi: 10.1080/14737140.2018.1500180. Epub 2018 Jul 23. Expert Rev Anticancer Ther. 2018. PMID: 29996062 Free PMC article. Review.
-
Mimickers of novel coronavirus disease 2019 (COVID-19) on chest CT: spectrum of CT and clinical features.Insights Imaging. 2021 Feb 3;12(1):12. doi: 10.1186/s13244-020-00956-6. Insights Imaging. 2021. PMID: 33533965 Free PMC article. Review.
-
Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses.Cancer Drug Resist. 2018;1:118-125. doi: 10.20517/cdr.2018.12. Epub 2018 Sep 19. Cancer Drug Resist. 2018. PMID: 30656289 Free PMC article.
-
Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario.Front Public Health. 2022 Jul 22;10:948520. doi: 10.3389/fpubh.2022.948520. eCollection 2022. Front Public Health. 2022. PMID: 35937253 Free PMC article.
References
-
- Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361:137–139. - PubMed
-
- Liu V, White D, Zakowski M, et al. Pulmonary toxicity associated with erlotinib. Chest. 2007;132:1042–1044. - PubMed
-
- Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006;24:2549–2556. - PubMed
-
- Chou CL, Ko HW, Wang CW, Yu CT, Kuo HP, Huang CD. Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma. Chang Gung Med J. 2010;33:100–105. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous